

# MERLIN\_001: A prospective registry study of a primary melanoma gene-signature to predict sentinel node (SN) status and determine its prognostic value for more accurate staging of SN-negative melanoma patients

Tina J. Hieken<sup>1</sup>, Michael E. Egger<sup>2</sup>, Christina V. Angeles<sup>3</sup>, Michael C. Lowe<sup>4</sup>, Erin E. Burke<sup>5</sup>, Edmund K. Bartlett<sup>6</sup>, John Hyingstrom<sup>7</sup>, and Vernon K. Sondak<sup>8</sup>  
<sup>1</sup>Department of Surgery, Mayo Clinic, Rochester, MN, USA; <sup>2</sup>Department of Surgery, University of Louisville, Louisville, KY, USA; <sup>3</sup>Department of Surgery, University of Michigan School of Medicine, Ann Arbor, MI, USA; <sup>4</sup>Department of Surgery, Emory University School of Medicine, Atlanta, GA, USA; <sup>5</sup>Division of Surgical Oncology, University of Kentucky, Lexington, KY, USA; <sup>6</sup>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>7</sup>Department of Surgery, Division of Surgical Oncology, University of Utah, Salt Lake City, UT, USA; <sup>8</sup>Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA

## Background

- Sentinel lymph node biopsy (SLNB) provides important staging and prognostic information that guides surveillance and adjuvant systemic therapy decisions [1]
- NCCN guidelines recommend “discuss and consider” SLNB for cutaneous melanoma (CM) patients with 5-10% risk of having nodal metastases and “recommend” SLNB for CM patients with > 10% risk [2]
- 85% of CM patients undergoing SLNB surgery do not have nodal metastasis [3]
- SLNB surgery is associated with a risk for complications such as seroma, infections and lymphedema [3]
- Furthermore, SN-negative CM patients still have a risk of recurrence and may be candidates for adjuvant therapy, therefore new techniques to identify SN-negative patients at highest risk of recurrence are clearly needed [4,5]
- CP-GEP, a model combining clinicopathological features (CP) and gene expression profile (GEP) of the primary tumor can potentially identify CM patients with a low risk of having nodal metastasis [6]
- The CP-GEP model has been clinically validated in multi-center retrospective studies both in Europe and in the US as well as in a Dutch prospective study during the Covid-19 pandemic [7-10]
- The current study aims to validate the CP-GEP model in a prospective multi-center registry study across the US

## Methods

### Study design

- ❖ Multi-center non-interventional clinical study with a consortium of surgical oncologists
- ❖ Prospectively validate the CP-GEP model in clinics across the US
- ❖ Results will be blinded to both patients and clinicians
- ❖ See Scheme 1 for the workflow process

### Study population

- ❖ Newly diagnosed T1-3cN0M0 primary cutaneous melanoma patients who are elected to undergo SLNB

### Target # patients

- ❖ 2,340 patients with cutaneous melanoma

### Enrollment Period


- ❖ 2 years (1<sup>st</sup> patient enrolled on 1<sup>st</sup> Sept, 2021)

## Study Objectives

Determine (1) predictive capability of CP-GEP model to identify primary cutaneous melanoma patients who can safely forgo SLNB and (2) to predict recurrence of melanoma after a negative SLNB.

ClinicalTrials.gov  
#NCT04759781

Corresponding author: Dr. Sondak  
vernson.sondak@moffitt.org



**Figure 1.** Sites participating the MERLIN\_001 Study: Mayo Clinic (Rochester, MN; Scottsdale, AZ; Jacksonville, FL), University of Louisville (Louisville, KY), University of Michigan (Ann Arbor, MI), Emory University (Atlanta GA), University of Kentucky (Lexington, KY), Memorial Sloan Kettering Cancer Center (New York, NY), University of Utah (Salt Lake City, UT), and Moffitt Cancer Center (Tampa, FL).

## Inclusion criteria

- ❖ Newly diagnosed melanoma:
  - ❖ T1b-T3 (BT ≤4.0 mm) N0M0
  - ❖ T1a (BT <0.8 mm) with adverse features (e.g. very high mitotic index (≥2/mm<sup>2</sup>), young age (<40 years), lymphovascular invasion, combination of these factors)
- ❖ Male or female, ≥ 18 years
- ❖ Elected to undergo SLN biopsy per treating physician’s recommendation


## Exclusion criteria

- ❖ Melanoma pathology report & diagnostic biopsy tissue unobtainable
- ❖ Regional and distant metastatic disease clinically present
- ❖ Any prior or concurrent primary invasive melanoma potentially draining to the same lymph node basin
- ❖ Documented prior history of primary invasive melanoma of T1b or greater at any site within last 5 years before current diagnosis
- ❖ Previous surgery in draining lymph node basin of current primary melanoma
- ❖ Ocular, vulvar, perianal, and mucosal melanoma and melanocytic tumors of uncertain malignant potential (MELTUMP) or atypical Spitz tumors

## References

- 1) Gershenwald et al 2017 CA Cancer Journal for Clinicians
- 2) NCCN Melanoma Guidelines 3.2022
- 3) Morton et al 2014 New England Journal of Medicine
- 4) Whiteman et al 2015 Journal of Investigative Dermatology
- 5) Luke et al 2022 Lancet
- 6) Bellomo et al 2020 JCO Precision Oncology
- 7) Mulder et al 2021 British Journal of Dermatology
- 8) Yousaf et al 2021 International Journal of Dermatology
- 9) Johansson et al 2021 European Journal of Surgical Oncology
- 10) Stassen et al 2022 EADO oral presentation

### Workflow Process MERLIN\_001



**Scheme 1.** Workflow process for the MERLIN\_001 Study.

Abbreviations: **PRO QoL:** Patient Related Outcomes, Quality of Life; **AE:** Adverse Events.